A total of @ pregnant women with primary CMV infection at @ to @ weeks of gestation were randomly assigned within @ weeks after the presumed onset of infection to receive hyperimmune globulin or placebo every @ weeks until @ weeks of gestation or until detection of CMV in amniotic fluid .